CAPLIPOINT

Caplin Point Laboratories Limited informed about its participation in the 16th Annual Global Investor Conference titled “TRINITY INDIA 2026”. The meeting will be held on May 28, 2026, Thursday, at 10:00 AM in Mumbai, involving one-to-one and group physical meetings with various analyst/institutional investors. The schedule is subject to changes.

Caplin Point Laboratories Limited announced the availability of the transcript for its Q4 FY2025-26 earnings call, which was held on Thursday, May 14, 2026. The call pertained to the company's financial performance for the quarter and year ended March 31, 2026. The transcript is accessible on the company's website.

New Filing detected. See link for details.

Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received USFDA final approval for its Abbreviated New Drug Application (ANDA) for Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag). This generic therapeutic equivalent version of Foscavir Injection is used to treat CMV retinitis in AIDS patients and HSV infection. The reference listed drug had US sales of approximately $15 million for the 12-month period ending March 2026.

The Board of Directors of Caplin Point Laboratories Limited, at its meeting on May 14, 2026, declared an Interim Dividend of INR 4.00 (200%) per equity share for the financial year ended March 31, 2026, with May 30, 2026, as the record date. The Board also approved the Audited standalone and consolidated financial results for the year ended March 31, 2026, which received an unmodified opinion from the statutory auditors. Amendments to the Code of Practices for Fair Disclosure of Unpublished Price Sensitive Information were also approved.

New Filing detected. See link for details.

New Filing detected. See link for details.